Bayer expects significant surge in number of U.S.
glyphosate cases
Send a link to a friend
[October 16, 2019] FRANKFURT
(Reuters) - Bayer <BAYGn.DE> expects the number of claims in the United
States related to Roundup herbicide to have surged in the third quarter,
as the German drugs and pesticides maker tries to reach a settlement
after earlier court rulings against it.
"With the substantial increase in plaintiff advertising this year, we
expect to see a significant surge in the number of plaintiff filings
over the third quarter," the company said in a written statement.
Bayer, which acquired Roundup and other glyphosate-based weed killers as
part of its $63 billion takeover of Monsanto last year, faces
potentially heavy litigation costs as plaintiffs claim Roundup causes
cancer, something Bayer disputes. [nL8N25520Y]
Bayer's shares have lost about 30% of their value since last August when
a California jury in the first such lawsuit found Monsanto should have
warned of the alleged cancer risks.
The drugmaker said in July that the number of U.S. plaintiffs in the
litigation had risen to 18,400 and it is due to provide an update on
Oct. 30, along with quarterly earnings.
Analysts at JP Morgan, citing an analysis of Missouri court data, said
in an Oct. 9 research note that the total number of glyphosate cases
could rise to more than 45,000.
However, several lawsuits have been delayed recently as mediator Ken
Feinberg tries to negotiate a settlement.[nL5N26R0MN]
[to top of second column] |
Environmental activists
protesting against the merger of Germany's pharmaceutical and
chemical maker Bayer AG with U.S. seeds and agrochemicals company
Monsanto, march through Germany's former capital Bonn before Bayer's
annual general shareholders meeting in Bonn, Germany, April 26,
2019. REUTERS/Thilo Schmuelgen/File Photo
The increase "may reflect a campaign by plaintiffs' lawyers and lead generators
to increase the volume of plaintiffs as quickly as possible in connection with
that process," Bayer said, adding that the number of plaintiffs was not an
indication of the merits of these cases.
Bayer has previously said that cases where lawyers expect to win the highest
damages tend to be filed first.
The head of Bayer's Crop Science unit, Liam Condon, already flagged a likely
increase in the number of cases in a newspaper interview earlier this month,
citing the prospect of a settlement and lawyers' efforts to recruit new
plaintiffs via media campaigns.
Bayer, which says regulators and extensive research have found glyphosate to be
safe, has previously said it was banking on U.S. appeals courts to reverse or
tone down three initial court rulings that have so far awarded tens of millions
of dollars to each plaintiff.
(Reporting by Ludwig Burger; Editing by Kirsten Donovan)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |